

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UMP HEALTHCARE HOLDINGS LIMITED

聯合醫務集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 722)

**(1) EXPIRY OF TENURE OF OFFICE OF INDEPENDENT
NON-EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR**

(2) APPOINTMENT OF DIRECTORS

**(3) CHANGE IN COMPOSITION OF BOARD COMMITTEES
AND**

(4) APPOINTMENT OF JOINT COMPANY SECRETARY

The Board hereby announces the following changes of the Company with effect from the conclusion of the AGM on 21 November 2025:

1. Dr. LI Kwok Tung, Donald has left his position as an independent non-executive Director upon the expiry of his tenure of office. He also ceased to be a member of the Audit Committee, the chairman of the Remuneration Committee and a member of the Nomination Committee;
2. Dr. LEE Kar Chung, Felix has left his position as a non-executive Director upon the expiry of his tenure of office;
3. Ms. CHENG Chi Man has been appointed as a non-executive Director;
4. Mrs. CHAN KUNG Wai Ying, Amy has been appointed as an independent non-executive Director, a member of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee; and
5. Mr. LEE Luen Wai, John has been redesignated as the chairman of the Remuneration Committee.

The Board further announces that Ms. TONG Mo Ting has been appointed as the joint company secretary of the Company with effect from 1 December 2025.

The board (the “**Board**”) of directors (the “**Directors**”) of UMP Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes of the Company:

EXPIRY OF TENURE OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The tenure of office of Dr. LI Kwok Tung, Donald (“**Dr. Donald Li**”) as an independent non-executive director expired upon the conclusion of the annual general meeting of the Company held on 21 November 2025 (the “**AGM**”). Dr. Donald Li had served as an independent non-executive director of the Company for over 10 years. In view of Rule 3.13A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Dr. Donald Li has agreed that he will not seek reappointment after the expiration of his tenure of office. He also ceased to be a member of the audit committee of the Company (the “**Audit Committee**”), the chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of the nomination committee of the Company (the “**Nomination Committee**”).

Dr. Donald Li has confirmed that he has no disagreement with the Board and there is no other matter that is required to be brought to the attention of the shareholders of the Company and/or the Stock Exchange.

The Board noted Dr. Donald Li’s decision not to seek reappointment after the expiration of his tenure of office and would like to express its gratitude to Dr. Donald Li for his valuable contributions to the Company over the past ten years. Dr. Donald Li has provided expert guidance to the Group, particularly in the areas of primary care and family medicine, and has contributed to strengthening the Group’s corporate governance framework. The Board extends its appreciation for his commitment and support.

EXPIRY OF TENURE OF OFFICE OF NON-EXECUTIVE DIRECTOR

The tenure of office of Dr. LEE Kar Chung, Felix (“**Dr. Felix Lee**”) as a non-executive director expired upon the conclusion of the AGM and Dr. Felix Lee decides not to renew the tenure of office after expiration due to his personal engagements.

Dr. Felix Lee has confirmed that he has no disagreement with the Board and there is no other matter that is required to be brought to the attention of the shareholders of the Company and/or the Stock Exchange.

The Board would like to express its gratitude to Dr. Felix Lee for his valuable contributions to the Company over the past ten years, particularly in supporting the Company’s listing ten years ago and driving the Group’s business development through various acquisition initiatives. The Board extends its appreciation for Dr. Felix Lee’s dedication to the strategic development of the Group.

APPOINTMENT OF DIRECTORS

Upon approval by the Board, Ms. CHENG Chi Man (“**Ms. Cheng**”) has been appointed as a non-executive Director; and Mrs. CHAN KUNG Wai Ying, Amy (“**Mrs. Amy Chan**”) has been appointed as an independent non-executive Director, a member of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee, both with effect from the conclusion of the AGM.

Biographical profile of Ms. Cheng

Ms. Cheng, aged 44, is an executive director of New World Development Company Limited, a vice-chairman and executive director of Chow Tai Fook Jewellery Group Limited, and a non-executive director of Giordano International Limited, all are listed public companies in Hong Kong. She was an independent director of Primavera Capital Acquisition Corporation, a company previously listed on the New York Stock Exchange, up until her resignation in December 2022. She is also the chief executive officer of Rosewood Hotel Group and an independent non-executive director of The Hongkong and Shanghai Banking Corporation Limited. Ms. Cheng holds a Bachelor of Arts Degree in Applied Mathematics with a concentration in Economics from Harvard University in the U.S.A. She is a member of the Council of The Chinese University of Hong Kong and a member of The Standing Committee on Disciplined Services Salaries and Conditions of Service of the Hong Kong Special Administrative Region. She is also the Vice-Governor of Guangdong Youth Development Foundation. Ms. Cheng is a member of the Thirteenth Guangdong Provincial Committee of The Chinese People’s Political Consultative Conference of The People’s Republic of China. Ms. Cheng is the niece of Dr. Sun Yiu Kwong, the cousin of Dr. Sun Man Kin, Michael and the cousin-in-law of Mr. Tsang On Yip, Patrick.

Ms. Cheng has entered into a letter of appointment with the Company as a non-executive Director for a term of one year commencing from the date of appointment, which term shall be automatically renewable for successive terms of one year. Ms. Cheng is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with to the articles of association of the Company. Under the terms of such appointment letter, the director’s fee payable to Ms. Cheng is fixed at the rate of HK\$240,000 per annum. The said director’s fee was determined with reference to fees paid by comparable companies, her time commitment and responsibilities and will be subject to review by the Remuneration Committee on an annual basis.

Save as disclosed above, as at the date of this announcement, Ms. Cheng does not (i) have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); (iii) hold any other position with the Company and any of its subsidiaries; and (iv) hold any directorship in any listed companies in Hong Kong or overseas in the last three years or other major appointments and professional qualifications. Save as disclosed herein, the Board is not aware of any other information relating to Ms. Cheng's appointment that need to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no matters concerning Ms. Cheng that need to be brought to the attention of the shareholders of the Company.

Biographical profile of Mrs. Amy Chan

Mrs. Amy Chan, aged 70, holds a Master of Arts from Leicester Polytechnic University, the United Kingdom. Mrs. Amy Chan has worked in KPMG from 1989 to 1993 and headed the firm's business development department. From 1993 to 2009, Mrs. Amy Chan served as the Chief Manager, Public Affairs of the Hospital Authority, gaining extensive expertise in managing external relations within the healthcare sector. From 2007 to 2009, she was the chief of the first China office of the Hospital Authority and was responsible for the strategic planning and management of initiatives related to Greater China. Currently, Mrs. Amy Chan serves as the Chairman of both the Child Development Matching Fund ("CDMF") and the Child Development Initiative Alliance ("CDIA"). In 2009, Mrs. Amy Chan began her involvement as a director at the CDMF at its inception stage to support the Hong Kong Special Administrative Region ("HKSAR") Government's Child Development Fund which is designed to combat intergenerational poverty. In 2014, Mrs. Amy Chan founded the CDIA with other community-minded individuals and became the chairperson in 2016.

Mrs. Amy Chan also actively contributes to healthcare and other community services. She is a Founding Director of the Hong Kong Stroke Fund and an advisor for the WeRISE Project, a community rehabilitation initiative that supports stroke patients and their families. She is also the Founding Chairman of the Charitable Foundation of Love and a board member of the Quality Mentorship Network. Mrs. Amy Chan was awarded the HKSAR Medal of Honour in 2025.

Mrs. Amy Chan has entered into a letter of appointment with the Company as an independent non-executive Director for a term of one year commencing from the date of appointment, which term shall be automatically renewable for successive terms of one year. Mrs. Amy Chan is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with to the articles of association of the Company. Under the terms of such appointment letter, the director's fee payable to Mrs. Amy Chan is fixed at the rate of HK\$240,000 per annum. The said director's fee was determined with reference to fees paid by comparable companies, her time commitment and responsibilities and will be subject to review by the Remuneration Committee on an annual basis.

Save as disclosed above, as at the date of this announcement, Mrs. Amy Chan does not (i) have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); (iii) hold any other position with the Company and any of its subsidiaries; and (iv) hold any directorship in any listed companies in Hong Kong or overseas in the last three years or other major appointments and professional qualifications. Mrs. Amy Chan confirmed (i) she has met the independence criteria as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries nor any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of their appointments. Save as disclosed herein, the Board is not aware of any other information relating to Mrs. Amy Chan's appointment that need to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no matters concerning Mrs. Amy Chan that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its welcome to Ms. Cheng and Mrs. Amy Chan for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the change of directors as set out above, the composition of the Board committees shall be changed as follows with effect from the conclusion of the AGM:

- (a) Dr. Donald Li ceased to be a member of the Audit Committee, the chairman of the Remuneration Committee and a member of the Nomination Committee;
- (b) Mrs. Amy Chan has been appointed as a member of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee; and
- (c) Mr. LEE Luen Wai, John has been redesignated as the chairman of the Remuneration Committee.

APPOINTMENT OF JOINT COMPANY SECRETARY

Ms. TONG Mo Ting (“**Ms. Tong**”) has been appointed as the joint company secretary of the Company with effect from 1 December 2025.

Ms. Tong is currently the legal counsel of the Group and has more than 10 years of legal and corporate governance experience. She obtained a Bachelor of Laws degree and a Postgraduate Certificate in Laws from The University of Hong Kong, and has been practicing as a solicitor in Hong Kong since 2015. Before joining the Group, she had provided legal and corporate services to various Hong Kong listed companies, specializing in general corporate and commercial affairs and regulatory compliance matters.

Following the said appointment, the joint company secretaries of the Company will be Mr. CHEUNG Chi Wah, Patrick and Ms. Tong. The Board would like to welcome Ms. Tong on her new appointment.

By Order of the Board
UMP Healthcare Holdings Limited
CHEUNG Chi Wah Patrick
Company Secretary

Hong Kong, 21 November 2025

As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman), Dr. SUN Man Kin, Michael (Vice-chairman and Co-Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Co-Chief Executive Officer), Mr. TSANG On Yip, Patrick, Dr. LEE Pak Cheung, Patrick; the Non-executive Director is Ms. CHENG Chi Man; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Mr. YEUNG Tak Bun and Mrs. CHAN KUNG Wai Ying, Amy.